Never miss out on the latest news!
Sign up to the Thrombosis Adviser newsletter.
This website is intended to provide information to an international audience outside the USA and UK
Follow the story of a patient with atrial fibrillation as they develop diabetes and renal impairment
© Bayer AG, 2020 | Approval number PP-XAR-ALL-1650-1
Professor Paolo Prandoni looks at the role of ASA in extended VTE treatment and discusses the recent EINSTEIN CHOICE study, which compared two doses of rivaroxaban to ASA for extended VTE treatment
© Bayer AG, 2020 | Approval number PP-XAR-ALL-1747-1